WallStSmart

Bioceres Crop Solutions Corp (BIOX)vsICL Israel Chemicals Ltd (ICL)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

ICL Israel Chemicals Ltd generates 2148% more annual revenue ($7.15B vs $318.16M). ICL leads profitability with a 3.2% profit margin vs -17.7%. BIOX appears more attractively valued with a PEG of 1.95. BIOX earns a higher WallStSmart Score of 50/100 (D+).

BIOX

Hold

50

out of 100

Grade: D+

Growth: 7.3Profit: 3.0Value: 6.7Quality: 5.0

ICL

Hold

45

out of 100

Grade: D+

Growth: 4.0Profit: 5.0Value: 4.7Quality: 7.0
Piotroski: 4/9Altman Z: 2.36
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for BIOX.

ICLSignificantly Overvalued (-236.3%)

Margin of Safety

-236.3%

Fair Value

$1.71

Current Price

$5.16

$3.45 premium

UndervaluedFair: $1.71Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

BIOX2 strengths · Avg: 9.0/10
Price/BookValuation
0.1x10/10

Reasonable price relative to book value

EPS GrowthGrowth
34.4%8/10

Earnings expanding 34.4% YoY

ICL1 strengths · Avg: 10.0/10
Price/BookValuation
1.1x10/10

Reasonable price relative to book value

Areas to Watch

BIOX4 concerns · Avg: 2.8/10
PEG RatioValuation
1.954/10

Expensive relative to growth rate

Market CapQuality
$23.61M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-19.0%2/10

ROE of -19.0% — below average capital efficiency

Revenue GrowthGrowth
-16.4%2/10

Revenue declined 16.4%

ICL4 concerns · Avg: 3.5/10
P/E RatioValuation
27.4x4/10

Moderate valuation

EPS GrowthGrowth
1.7%4/10

1.7% earnings growth

Return on EquityProfitability
4.6%3/10

ROE of 4.6% — below average capital efficiency

Profit MarginProfitability
3.2%3/10

3.2% margin — thin

Comparative Analysis Report

WallStSmart Research

Bull Case : BIOX

The strongest argument for BIOX centers on Price/Book, EPS Growth.

Bull Case : ICL

The strongest argument for ICL centers on Price/Book.

Bear Case : BIOX

The primary concerns for BIOX are PEG Ratio, Market Cap, Return on Equity.

Bear Case : ICL

The primary concerns for ICL are P/E Ratio, EPS Growth, Return on Equity. Thin 3.2% margins leave little buffer for downturns.

Key Dynamics to Monitor

BIOX profiles as a turnaround stock while ICL is a value play — different risk/reward profiles.

ICL carries more volatility with a beta of 1.01 — expect wider price swings.

ICL is growing revenue faster at 6.2% — sustainability is the question.

ICL generates stronger free cash flow (25M), providing more financial flexibility.

Bottom Line

BIOX scores higher overall (50/100 vs 45/100). Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Bioceres Crop Solutions Corp

BASIC MATERIALS · AGRICULTURAL INPUTS · USA

Bioceres Crop Solutions Corp.

ICL Israel Chemicals Ltd

BASIC MATERIALS · AGRICULTURAL INPUTS · USA

ICL Group Ltd, is a company specialized in minerals and chemical products worldwide. The company is headquartered in Tel Aviv, Israel.

Visit Website →

Want to dig deeper into these stocks?